3 September 2024 in Nucleic Acids Research
Proteolysis-targeting chimera (PROTAC) is an emerging therapeutic technology that leverages the ubiquitin-proteasome system to target protein degradation. Due to its event-driven mechanistic characteristics, PROTAC has the potential to regulate traditionally non-druggable targets. Recently, AI-aided drug design has accelerated the development of PROTAC drugs. However, the rational design of PROTACs remains a considerable challenge. Here, we present an updated online database, PROTAC-DB 3.0. In this third version, we have expanded the database to include 6111 PROTACs (87% increase compared to the 2.0 version). Additionally, the database now contains 569 warheads (small molecules targeting the protein), 2753 linkers, and 107 E3 ligands (small molecules recruiting E3 ligases). The number of target-PROTAC-E3 ternary complex structures has also increased to 959. Recognizing the importance of druggability in PROTAC design, we have incorporated pharmacokinetic data to PROTAC-DB 3.0. To enhance user experience, we have added features for sorting based on molecular similarity and literature publication date. PROTAC-DB 3.0 is accessible at http://cadd.zju.edu.cn/protacdb/.
7 March 2025 in Science Advances
Large language models (LLMs) have shown remarkable advancements in chemistry and biomedical research, acting as versatile foundation models for various tasks. We introduce AMP-Designer, an LLM-based approach, for swiftly designing antimicrobial peptides (AMPs) with desired properties. Within 11 days, AMP-Designer achieved the de novo design of 18 AMPs with broad-spectrum activity against Gram-negative bacteria. In vitro validation revealed a 94.4% success rate, with two candidates demonstrating exceptional antibacterial efficacy, minimal hemotoxicity, stability in human plasma, and low potential to induce resistance, as evidenced by significant bacterial load reduction in murine lung infection experiments. The entire process, from design to validation, concluded in 48 days. AMP-Designer excels in creating AMPs targeting specific strains despite limited data availability, with a top candidate displaying a minimum inhibitory concentration of 2.0 micrograms per milliliter against Propionibacterium acnes . Integrating advanced machine learning techniques, AMP-Designer demonstrates remarkable efficiency, paving the way for innovative solutions to antibiotic resistance.
13 May 2025 in Nature Communications
The integration of large language models (LLMs) into drug design is gaining momentum; however, existing approaches often struggle to effectively incorporate three-dimensional molecular structures. Here, we present Token-Mol, a token-only 3D drug design model that encodes both 2D and 3D structural information, along with molecular properties, into discrete tokens. Built on a transformer decoder and trained with causal masking, Token-Mol introduces a Gaussian cross-entropy loss function tailored for regression tasks, enabling superior performance across multiple downstream applications. The model surpasses existing methods, improving molecular conformation generation by over 10% and 20% across two datasets, while outperforming token-only models by 30% in property prediction. In pocket-based molecular generation, it enhances drug-likeness and synthetic accessibility by approximately 11% and 14%, respectively. Notably, Token-Mol operates 35 times faster than expert diffusion models. In real-world validation, it improves success rates and, when combined with reinforcement learning, further optimizes affinity and drug-likeness, advancing AI-driven drug discovery.
4 August 2025 in Nature Machine Intelligence
Therapeutic peptides represent the forefront of drug discovery, offering potent and safe alternatives to traditional small molecules. However, their weak and context-dependent nature complicates the efficient virtual screening and structural characterization of protein–peptide patterns. Here we introduce RAPiDock, a diffusion generative model designed for rational, accurate and rapid protein–peptide docking at an all-atomic level. RAPiDock efficiently reduces the sampling space by incorporating physical constraints and uses a bi-scale graph to effectively capture multidimensional structural information while balancing efficiency. In addition, the model uses a Clebsch–Gordan tensor product-based architecture to ensure physical symmetry. RAPiDock outperforms existing tools in prediction of protein–peptide-binding patterns, achieving a 93.7% success rate at top-25 predictions (13.4% higher than AlphaFold2-Multimer), with an execution speed of 0.35 seconds per complex (~270 times faster than AlphaFold2-Multimer). Extensive experiments demonstrate RAPiDock’s remarkable ability to handle 92 types of residue including posttranslational modifications, accurately predict subtle docking patterns, successfully identify multiple potential peptide-binding sites in global docking and serve as a powerful tool for high-throughput virtual screening with structural precision. All these push the boundaries of efficient protein–peptide docking in multiple real-application scenarios.
29 April 2025 in Chemical Science
TRAP is a framework that leverages contrastive learning to integrate structural and sequence features for predicting TCR–pMHC binding probability, demonstrating superior generalization on unseen epitopes and maintaining a low false positive rate.
24 June 2026 in Nature Protocols